Posts by: Marisa Wexler MS

Marisa Wexler MS

Marisa, a science writer, holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

February 5, 2020February 5, 2020

Mouse Study Finds Genetic Identity of Embryonic Lung Progenitor Cells

cystic fibrosis, News

The genetic programming that causes embryonic cells to differentiate into lung cells was described for the first time in a study in mice. Researchers say that understanding the genetic ... Read more

January 23, 2020January 23, 2020

Enrollment Nearly Complete for Phase 2 Clinical Trials Testing ELX-02 in CF Patients

cystic fibrosis, News

Enrollment is nearing completion for two Phase 2 clinical trials testing the experimental treatment ELX-02 in people with cystic fibrosis (CF), according to Eloxx Pharmaceuticals, the company developing ELX-02. ... Read more

January 22, 2020January 22, 2020

CF Foundation Awards $700K to Support Work into Treatments for B. cepacia Infections

cystic fibrosis, News

The Cystic Fibrosis (CF) Foundation awarded a nearly $700,000 contract to Calibr, the drug discovery and development arm of Scripps Research, to support projects aiming to identify compounds that could ... Read more

December 11, 2019December 11, 2019

European Commission Approves Kalydeco for Children as Young as Six Months

cystic fibrosis, News

The European Commission has approved a label extension for Kalydeco (ivacaftor), allowing the therapy to be used in infants with cystic fibrosis (CF) who are between the ages of ... Read more

November 14, 2019November 14, 2019

Vertex Reaches Agreement for CF Medications in Northern Ireland and Wales

cystic fibrosis, News

The Regional Pharmaceutical Procurement Service in Northern Ireland and the National Health Service (NHS) Wales have reached an agreement with Vertex Pharmaceuticals that will allow people with cystic fibrosis ... Read more

October 24, 2019October 25, 2019

Cystic Fibrosis Foundation Applauds FDA Approval of Trikafta

cystic fibrosis, News

The Cystic Fibrosis Foundation (CFF) is celebrating the United States Food and Drug Administration’s decision to approve Trikafta. The therapy — a triple combo based on elexacaftor, tezacaftor, and ivacaftor, which is being ... Read more

October 23, 2019October 23, 2019

Europe’s CHMP Issues Positive Opinion on Kalydeco Use in Infants

cystic fibrosis, News

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the use of Kalydeco (ivacaftor) in infants ages ... Read more

October 16, 2019October 16, 2019

Chelsea Financial Services Supporting Boomer Esiason Foundation, CF Research at NYC Marathon

cystic fibrosis, News

John Pirozzi, a representative of Chelsea Financial Services, will participate in the TCS New York City Marathon to raise money for cystic fibrosis research, the company announced. Pirozzi is ... Read more

October 10, 2019October 10, 2019

FDA Designates Vast’s BIOC11 a Qualified Infectious Disease Product

cystic fibrosis, News

The U.S. Food and Drug Administration (FDA) has designated Vast Therapeutics’ BIOC11 a Qualified Infectious Disease Product (QIDP) for the treatment of people with cystic fibrosis (CF) who have chronic ... Read more

October 8, 2019October 8, 2019

Experts Highlight Obstacles in Delivering New CF Therapies

cystic fibrosis

Care for cystic fibrosis (CF) has improved substantially in recent decades, but there are still challenges ahead, particularly in ensuring that all patients have access to the best available ... Read more